Cytoflavin's neuroprotective effect in acute ischemic stroke: a systematic review and meta-analysis
Neuroprotektiver Effekt von Cytoflavin beim akuten ischämischen Schlaganfall: systematische Übersichtsarbeit und Metaanalyse
Frontiers in Stroke · 30.10.2026 · 5
DOI: 10.3389/fstro.2026.1775376 ↗Auf einen Blick
Neun Studien mit 3.254 Teilnehmenden untersuchten Cytoflavin bei AIS. Verbesserungen zeigten sich bei NIHSS und Barthel Index; für MMSE und mRS waren die Effekte geringer.
Fragestellung
Wie wirksam ist Cytoflavin bei akutem ischämischem Schlaganfall hinsichtlich neurologischer Erholung, funktioneller Unabhängigkeit, Kognition und Infarktvolumen?
Methode
Systematische Übersichtsarbeit und Metaanalyse; Suche in mehreren Datenbanken; random-effects Modelle; Verzerrungsrisiko mit Cochrane Risk of Bias Tool und Newcastle-Ottawa Scale.
Ergebnisse
NIHSS: MD −2,63 (95 %-KI −3,15 bis −2,10; moderate certainty). Barthel Index: MD 19,29 (95 %-KI 9,52 bis 29,07; moderate certainty). MMSE: MD +6,93 (95 %-KI 1,39 bis 12,47; low certainty).
Einschränkungen
Hohe Heterogenität (I2 0 % bis 100 %); methodische Einschränkungen; unterschiedliche Effekte beim Infarktvolumen je nach Messzeitpunkt.
Schlussfolgerung der Autor:innen
Cytoflavin zeigt beim akuten ischämischen Schlaganfall vielversprechende neuroprotektive Effekte. Weitere große, hochwertige Studien sind nötig, um Wirksamkeit und Behandlungsprotokolle zu bestätigen.
Kernaussagen
- NIHSS verbesserte sich: MD −2,63 (95 %-KI −3,15 bis −2,10)
- Barthel Index verbesserte sich: MD 19,29 (95 %-KI 9,52 bis 29,07)
- Hohe Heterogenität und methodische Limitationen schränken die Aussagekraft ein
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Systematische Übersicht in der Zeitschrift Frontiers in Stroke, online erschienen am 30.10.2026. Verfasst von Retnaningsih Retnaningsih und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Faculty of Medicine, University of Diponegoro, Semarang, Indonesia. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Schlaganfall
Abstract (Originalsprache)
Acute ischemic stroke (AIS) remains a leading cause of long-term disability globally. While reperfusion therapies are effective, there is a growing need for adjunct neuroprotective strategies to minimize secondary brain injury. Cytoflavin, a metabolic and antioxidant compound, has shown potential neuroprotective effects. However, its clinical efficacy remains underexplored. This systematic review and meta-analysis aim to evaluate the efficacy of Cytoflavin in AIS, focusing on neurological recovery (NIHSS), functional independence (Barthel Index), cognitive performance (MMSE), and infarct volume. A systematic search was conducted across multiple databases for studies evaluating Cytoflavin in AIS. Nine studies were included, with a combined enrollment of 3,254 participants across treatment arms (sample sizes reported per arm); the number of unique participants contributing to each pooled outcome was smaller after correcting for shared control groups and repeated-measures overlap across evaluation time points (e.g., 1,379 for NIHSS). Data were analyzed using random-effects models; where a shared control group was compared against two Cytoflavin dose arms within the same study, the control group was split proportionally between the two comparisons to avoid double-counting participants (unit-of-analysis correction). Risk of bias was assessed using Cochrane Risk of Bias tool and Newcastle-Ottawa Scale. Cytoflavin significantly improved NIHSS scores (MD = −2.63, 95% CI: −3.15 to −2.10; moderate certainty) and Barthel Index (MD = 19.29, 95% CI: 9.52 to 29.07; moderate certainty), and showed improvements of low certainty in MMSE scores (MD = +6.93, 95% CI: 1.39 to 12.47) and mRS scores (MD = −0.41, 95% CI: −0.74 to −0.09), the latter derived from continuous summary statistics for an inherently ordinal scale (see Limitations). For infarct volume, effects diverged by evaluation time point: a marginal increase was observed at Day-10 (MD = +0.17 cm 3 , based on a single study), while a non-significant reduction was observed at Day-21 (MD = −4.73 cm 3 , 95% CI: −11.41 to 1.95; very low certainty). High heterogeneity (I 2 ranging from 0% to 100%) was observed across outcomes and persisted after the unit-of-analysis correction, indicating genuine clinical and methodological diversity across studies. In conclusion, cytoflavin shows promising neuroprotective effects in AIS. However, due to heterogeneity and methodological limitations, further large-scale, high-quality studies are needed to confirm its efficacy and optimize treatment protocols. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251112430 , identifier: CRD420251112430.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, Faculty of Medicine, University of Diponegoro, Semarang, Indonesia.
Zitieren
APA
Retnaningsih, R., Tugasworo, D., Arinta Puspita, W., Elvika, C., & Pratama, A. A. (2026). Cytoflavin's neuroprotective effect in acute ischemic stroke: a systematic review and meta-analysis. Frontiers in Stroke, 5. https://doi.org/10.3389/fstro.2026.1775376
Vancouver
Retnaningsih R, Tugasworo D, Arinta Puspita W, Elvika C, Pratama AA. Cytoflavin's neuroprotective effect in acute ischemic stroke: a systematic review and meta-analysis. Frontiers in Stroke. 2026;5. doi:10.3389/fstro.2026.1775376
BibTeX
@article{Retnaningsih2026,
author = {Retnaningsih, Retnaningsih and Tugasworo, Dodik and Arinta Puspita, Wati and Elvika, Chandra and Pratama, Arrizki Azka},
title = {Cytoflavin's neuroprotective effect in acute ischemic stroke: a systematic review and meta-analysis},
journal = {Frontiers in Stroke},
year = {2026},
volume = {5},
doi = {10.3389/fstro.2026.1775376}
}
EUVIMED